|
000
| 03615nam 2200421zi 4500 |
|---|
| 001 | 9.931658 |
|---|
| 003 | CaOODSP |
|---|
| 005 | 20240108150927 |
|---|
| 006 | m o d f |
|---|
| 007 | cr mn||||||||| |
|---|
| 008 | 231220e202308 onca ob f000 0 eng d |
|---|
| 020 | |a9780660693842 |
|---|
| 040 | |aCaOODSP|beng|erda|cCaOODSP |
|---|
| 043 | |an-cn--- |
|---|
| 045 | |ay1y2 |
|---|
| 086 | 1 |aHP5-177/2023E-PDF |
|---|
| 245 | 00|aHorizontal evaluation of the Canadian Drugs and Substances Strategy : |bevaluation report / |cprepared by the Office of Audit and Evaluation, Health Canada and the Public Health Agency of Canada. |
|---|
| 264 | 1|aOttawa, ON : |bHealth Canada and the Public Health Agency of Canada = Santé Canada et l'Agence de la santé publique du Canada, |cAugust 2023. |
|---|
| 300 | |a1 online resource (87 pages) : |bcolour illustrations |
|---|
| 336 | |atext|btxt|2rdacontent |
|---|
| 337 | |acomputer|bc|2rdamedia |
|---|
| 338 | |aonline resource|bcr|2rdacarrier |
|---|
| 500 | |aIssued also in French under title: Évaluation horizontale de la Stratégie canadienne sur les drogues et autres substances : rapport d'évaluation. |
|---|
| 500 | |a"Pub.: 230565"--Verso of cover. |
|---|
| 504 | |aIncludes bibliographical references (pages 77-87). |
|---|
| 520 | |a"Canada is experiencing an unprecedented rate of substance use-related deaths and harms due to a number of complex, interrelated factors. The Canadian Drugs and Substances Strategy (CDSS), which was first announced in 2016, sets out the federal government's comprehensive, collaborative, compassionate, and evidence-based approach to drug policy that focuses on substance use as a public health issue. The CDSS replaced the National Anti-Drug Strategy (NADS), which was established in 2006, and the lead changed from the Department of Justice to Health Canada. From 2017 to 2022, Health Canada coordinated federal investments and activities across the full spectrum of legal and illegal substances under four pillars: prevention, treatment, harm reduction, and enforcement. ... This evaluation looked at all funded partners' activities from 2017-18 to 2021-22 under both horizontal initiatives and focused on progress made toward delivering on Pillar objectives and shared outcomes, including HC's Substance Use and Addictions Program (SUAP) and PHAC's Harm Reduction Fund activities to address Financial Administration Act requirements. However, activities related to tobacco and cannabis, including SUAP projects for these substances, were excluded from this evaluation as there were separate evaluations assessing activities related to these two substances"--Executive summary, page 5. |
|---|
| 650 | 0|aDrug abuse|xGovernment policy|zCanada|xEvaluation. |
|---|
| 650 | 0|aSubstance abuse|xGovernment policy|zCanada|xEvaluation. |
|---|
| 650 | 0|aDrug abuse|zCanada|xPrevention|xEvaluation. |
|---|
| 650 | 0|aSubstance abuse|zCanada|xPrevention|xEvaluation. |
|---|
| 650 | 0|aDrug abuse|xTreatment|zCanada|xEvaluation. |
|---|
| 650 | 0|aSubstance abuse|xTreatment|zCanada|xEvaluation. |
|---|
| 710 | 1 |aCanada. |bHealth Canada. |bOffice of Audit and Evaluation, |eissuing body. |
|---|
| 710 | 2 |aPublic Health Agency of Canada. |bOffice of Audit and Evaluation, |eissuing body. |
|---|
| 775 | 08|tÉvaluation horizontale de la Stratégie canadienne sur les drogues et autres substances : |w(CaOODSP)9.931660 |
|---|
| 856 | 40|qPDF|s1.53 MB|uhttps://publications.gc.ca/collections/collection_2024/sc-hc/HP5-177-2023-eng.pdf |
|---|
| 856 | 4 |qHTML|sN/A|uhttps://www.canada.ca/en/health-canada/corporate/transparency/corporate-management-reporting/evaluation/canadian-drugs-substances-strategy.html |
|---|